Drug concentrations after topical and oral antiretroviral pre-exposure prophylaxis: implications for HIV prevention in women.
作者信息
Karim Salim S Abdool, Kashuba Angela D M, Werner Lise, Karim Quarraisha Abdool
机构信息
Centre for the AIDS Programme of Research in South Africa, University of KwaZulu-Natal, Durban, South Africa.
出版信息
Lancet. 2011 Jul 16;378(9787):279-81. doi: 10.1016/S0140-6736(11)60878-7.
Abstract
摘要
相似文献
1
Drug concentrations after topical and oral antiretroviral pre-exposure prophylaxis: implications for HIV prevention in women.局部和口服抗逆转录病毒暴露前预防后的药物浓度：对女性预防艾滋病毒的意义。
Lancet. 2011 Jul 16;378(9787):279-81. doi: 10.1016/S0140-6736(11)60878-7.
2
Antiretrovirals for HIV prevention: translating promise into praxis.用于预防艾滋病病毒的抗逆转录病毒药物：将希望转化为实践。
Lancet. 2011 Jul 16;378(9787):206-8. doi: 10.1016/S0140-6736(11)61056-8.
3
Tenofovir-based preexposure prophylaxis for HIV infection among African women.基于替诺福韦的暴露前预防用于非洲女性的HIV感染
N Engl J Med. 2015 Feb 5;372(6):509-18. doi: 10.1056/NEJMoa1402269.
4
Concentrations of tenofovir and emtricitabine in saliva: implications for preexposure prophylaxis of oral HIV acquisition.唾液中替诺福韦和恩曲他滨的浓度：对口腔 HIV 感染暴露前预防的影响。
Antimicrob Agents Chemother. 2011 Oct;55(10):4905-7. doi: 10.1128/AAC.00120-11. Epub 2011 Jul 25.
5
Antiretroviral prophylaxis: a defining moment in HIV control.抗逆转录病毒预防：HIV 控制中的一个决定性时刻。
Lancet. 2011 Dec 17;378(9809):e23-5. doi: 10.1016/S0140-6736(11)61136-7. Epub 2011 Jul 21.
6
Antiretroviral vaginal gel shows promise against HIV.抗逆转录病毒阴道凝胶有望对抗艾滋病毒。
Lancet. 2010 Jul 31;376(9738):320. doi: 10.1016/s0140-6736(10)61123-3.
7
Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis.女性生殖道中的抗逆转录病毒药物暴露：对口服暴露前和暴露后预防的影响。
AIDS. 2007 Sep 12;21(14):1899-907. doi: 10.1097/QAD.0b013e328270385a.
8
FDA paves the way for pre-exposure HIV prophylaxis.美国食品药品监督管理局为暴露前预防艾滋病铺平道路。
Lancet. 2012 Jul 28;380(9839):325. doi: 10.1016/s0140-6736(12)61235-5.
9
Study halted: no benefit seen from antiretroviral pill in preventing HIV in women.研究停止：抗逆转录病毒药丸在预防女性感染艾滋病毒方面未见益处。
JAMA. 2011 May 18;305(19):1952. doi: 10.1001/jama.2011.649.
10
AIDS: Drugs that prevent HIV infection.艾滋病：预防艾滋病毒感染的药物。
Nature. 2011 Jan 20;469(7330):306-7. doi: 10.1038/469306a.
引用本文的文献
1
The Real-World Effectiveness of Human Immunodeficiency Virus Pre-Exposure Prophylaxis in Adults in Alberta, Canada: A Retrospective Population-Based Cohort Study.加拿大艾伯塔省成人艾滋病病毒暴露前预防的真实世界有效性：一项基于人群的回顾性队列研究。
Can J Infect Dis Med Microbiol. 2025 Aug 10;2025:9340622. doi: 10.1155/cjid/9340622. eCollection 2025.
2
Vaginal pharmacomicrobiomics modulates risk of persistent and recurrent bacterial vaginosis.阴道药物微生物组学调节持续性和复发性细菌性阴道病的风险。
NPJ Biofilms Microbiomes. 2025 Jul 1;11(1):115. doi: 10.1038/s41522-025-00748-0.
3
Understanding the influence of the microbiome on childhood infections.了解微生物组对儿童感染的影响。
Expert Rev Anti Infect Ther. 2024 Jul;22(7):529-545. doi: 10.1080/14787210.2024.2340664. Epub 2024 Apr 12.
4
Phase 1 randomized pharmacokinetic and safety study of a 90-day tenofovir vaginal ring in the United States.美国开展的为期 90 天替诺福韦阴道环的 1 期随机药代动力学和安全性研究。
J Int AIDS Soc. 2024 Mar;27(3):e26223. doi: 10.1002/jia2.26223.
5
Tenofovir Douche as HIV Preexposure Prophylaxis for Receptive Anal Intercourse: Safety, Acceptability, Pharmacokinetics, and Pharmacodynamics (DREAM 01).替诺福韦阴道冲洗剂作为接受性肛交的 HIV 暴露前预防：安全性、可接受性、药代动力学和药效学（DREAM 01）。
J Infect Dis. 2024 Apr 12;229(4):1131-1140. doi: 10.1093/infdis/jiad535.
6
How a menu of adherence support strategies facilitated high adherence to HIV prevention products among adolescent girls and young women in sub-Saharan Africa: a mixed methods analysis.一种包含多种坚持支持策略的菜单如何促进撒哈拉以南非洲地区的青少年女孩和年轻女性对艾滋病毒预防产品的高坚持率：一项混合方法分析。
J Int AIDS Soc. 2023 Nov;26(11):e26189. doi: 10.1002/jia2.26189.
7
Next generation 3D-printed intravaginal ring for prevention of HIV and unintended pregnancy.用于预防 HIV 和非意愿妊娠的下一代 3D 打印阴道环。
Biomaterials. 2023 Oct;301:122260. doi: 10.1016/j.biomaterials.2023.122260. Epub 2023 Aug 3.
8
Randomized controlled phase IIa clinical trial of safety, pharmacokinetics and pharmacodynamics of tenofovir and tenofovir plus levonorgestrel releasing intravaginal rings used by women in Kenya.在肯尼亚女性中进行的替诺福韦以及替诺福韦加左炔诺孕酮缓释阴道环的安全性、药代动力学和药效学的随机对照IIa期临床试验。
Front Reprod Health. 2023 Jun 13;5:1118030. doi: 10.3389/frph.2023.1118030. eCollection 2023.
9
A phase I study to assess safety, pharmacokinetics, and pharmacodynamics of a vaginal insert containing tenofovir alafenamide and elvitegravir.一项评估含有替诺福韦艾拉酚胺和艾维雷韦的阴道插入剂的安全性、药代动力学和药效学的 I 期研究。
Front Cell Infect Microbiol. 2023 Apr 19;13:1130101. doi: 10.3389/fcimb.2023.1130101. eCollection 2023.
10
Women for science and science for women: Gaps, challenges and opportunities towards optimizing pre-exposure prophylaxis for HIV-1 prevention.促进女性参与科学和科学服务于女性：填补差距、应对挑战、把握机遇，以优化 HIV-1 预防的暴露前预防措施。
Front Immunol. 2022 Dec 6;13:1055042. doi: 10.3389/fimmu.2022.1055042. eCollection 2022.
本文引用的文献
1
Microbicides & their implications in HIV prevention.杀微生物剂及其在艾滋病预防中的意义。
Indian J Med Res. 2010 Dec;132(6):656-9.
2
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.男男性行为人群 HIV 预防的暴露前药物预防。
N Engl J Med. 2010 Dec 30;363(27):2587-99. doi: 10.1056/NEJMoa1011205. Epub 2010 Nov 23.
3
Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women.替诺福韦凝胶作为一种抗逆转录病毒的杀微生物剂，用于预防女性感染艾滋病毒的有效性和安全性。
Science. 2010 Sep 3;329(5996):1168-74. doi: 10.1126/science.1193748. Epub 2010 Jul 19.
4
Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis.女性生殖道中的抗逆转录病毒药物暴露：对口服暴露前和暴露后预防的影响。
AIDS. 2007 Sep 12;21(14):1899-907. doi: 10.1097/QAD.0b013e328270385a.
Zotero 插件